Stevens-Johnson Syndrome clinical trials
The registry lists 40 studies for Stevens-Johnson Syndrome across more than 10 countries. 8 are recruiting or about to start. 28 of them are mainly about Stevens-Johnson Syndrome (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-28.
Get an email when these change. Save the Stevens-Johnson Syndrome studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Massachusetts Eye and Ear Infirmary (3) · Assistance Publique - Hôpitaux de Paris (2) · Massachusetts General Hospital (2) · Chulalongkorn University (2) · Mahidol University (2) · Hospices Civils de Lyon (2) · Seoul National University Hospital (2) · University of Pernambuco (1)
What is being tested here
Drugs under test in Stevens-Johnson Syndrome studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 4
- Feb 2027Autologous Serum Obtained by a Closed-Circuit Collection Device · GIANCARLO FATOBENE
- Apr 2027LYell SYndrome MEsenchymal Stromal Cells Treatment · Assistance Publique - Hôpitaux de Paris
- Jun 2027Subconjunctival Humira for Boston Keratoprosthesis · Massachusetts Eye and Ear Infirmary
- Jun 2027HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness · Haiphong University of Medicine and Pharmacy
Who these studies take
Of the 4 Stevens-Johnson Syndrome studies recruiting now, 2 (50%) set no upper age limit and 2 (50%) stop at 75 or younger. 1 (25%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (25%) | 1 (25%) |
| 18 | 4 (100%) | 4 (100%) |
| 30 | 4 (100%) | 4 (100%) |
| 40 | 4 (100%) | 4 (100%) |
| 50 | 4 (100%) | 4 (100%) |
| 65 | 4 (100%) | 4 (100%) |
| 75 | 3 (75%) | 3 (75%) |
| 85 | 2 (50%) | 2 (50%) |
Across all 40 studies, recruiting or not: 13% stop at 75 or younger and 5% at 65; 33% take children; 0% are for women only and 3% for men only; 15% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 13, 2026.
Results posted1
Studies
Recruiting first, then most recently updated. Showing 40 of 40. search them.
- Subconjunctival Humira for Boston KeratoprosthesisNot yet recruitingNCT06926478Phase 11 country
- HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-EffectivenessNot yet recruitingNCT07369622Phase 4
- New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.Not yet recruitingNCT07110662Phase 1/21 country
- LYell SYndrome MEsenchymal Stromal Cells TreatmentRecruitingNCT04711200Phase 1/21 country
- Severe Bullous Drug Eruption and FilgrastimRecruitingNCT04651439Phase 2/31 country
- Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal NecrolysisRecruitingNCT06119490Early Phase 11 country
- Drug Reactions Sampling (COLLECTIONTOXIDERMIES)RecruitingNCT036592271 country
- Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet TransplantationAvailableNCT021497321 country
- Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host DiseaseTerminatedNCT04313725Not applicable1 country
- Autologous Serum Obtained by a Closed-Circuit Collection DeviceActive, not recruitingNCT07014059Phase 21 country
- Cultivated Stem Cell Transplantation for the Treatment of Limbal Stem Cell DeficiencyCompletedNCT00845117Not applicable1 country
- Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal NecrolysisWithdrawnNCT03585946
- G-CSF in the Treatment of Toxic Epidermal NecrolysisCompletedNCT02739295Phase 41 country
- NATIENS: Optimal Management and Mechanisms of SJS/TENCompletedNCT02987257Phase 31 country
- Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TENCompletedNCT06474078Not applicable1 country
- Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis ImplantationCompletedNCT02945176Not applicable1 country
- SJS/TEN or Other Cutaneous Adverse Eevents Induced by Immune Checkpoint Inhibitors (ICIs) vs. Non-ICIsCompletedNCT065220481 country
- Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis.Active, not recruitingNCT05520086Phase 1/21 country
- Vitamin D Levels in Non-immediate Drug Hypersensitivity Case-control StudyCompletedNCT062631401 country
- Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot StudyWithdrawnNCT02795143Not applicable1 country
- Nutritional and Metabolic Management of Toxidermia Patients Requiring Intensive Care (TEN Metabolism)CompletedNCT05320653
- Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian PopulationStatus unknownNCT052849291 country
- Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal NecrolysisStatus unknownNCT05145959Not applicable1 country
- Use of Cross-linked Donor Corneas as Carriers for the Boston KeratoprosthesisCompletedNCT01582880Phase 1/21 country
- Topical Clobetasol for the Treatment of Toxic Epidermal NecrolysisWithdrawnNCT02319616Phase 1/21 country
- Severe Cutaneous Adverse Reactions in ThailandStatus unknownNCT025749881 country
- Minor Salivary Gland Transplantation for Cicatrizing ConjunctivitisStatus unknownNCT03839069Not applicable1 country
- HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse ReactionsStatus unknownNCT03184597Not applicable1 country
- Topical Infliximab in Autoimmune Eyes With KeratoprosthesisWithdrawnNCT02126020Phase 1/22 countries
- HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse ReactionStatus unknownNCT03046914Not applicable1 country
- Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal NecrolysisTerminatedNCT02037347Phase 1/21 country
- Salivary Gland Transplantation in the Treatment of Dry Eye in Patients With Stevens-Johnson Syndrome.CompletedNCT01178242Not applicable1 country
- Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)WithdrawnNCT01256489Phase 1/21 country
- Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.CompletedNCT01696500Phase 31 country
- Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)WithdrawnNCT00372723Phase 2
- Lamictal in the Treatment of Post-Herpetic NeuralgiaTerminatedNCT00295776Phase 2/31 country
- Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry EyeCompletedNCT01488396Phase 41 country
- Corneal Epitheliotropic Factors in Autologous Serum Eye Drops in Nonautoimmune and Stevens-Johnson Syndrome With Dry EyeStatus unknownNCT011223031 country
- Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface TransplantationCompletedNCT00346450Phase 31 country
- Stevens-Johnson Syndrome AntimicrobialCompletedNCT008440381 country